| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1991.9.4.625 |
| P698 | PubMed publication ID | 2066758 |
| P2093 | author name string | R Reddy | |
| A Legaspi | |||
| L Chua | |||
| S Richman | |||
| K Sridhar | |||
| B Ardalan | |||
| S Waldman | |||
| P Benedetto | |||
| E M Tian | |||
| L Morrell | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal carcinoma | Q25493920 |
| fluorouracil | Q238512 | ||
| P304 | page(s) | 625-630 | |
| P577 | publication date | 1991-04-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma | |
| P478 | volume | 9 |
| Q63641990 | 2 Role of immunohistochemical expression of p53 in colorectal carcinoma |
| Q34127889 | A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy |
| Q55064705 | A new complication of chemotherapy administered via permanent indwelling central venous catheter |
| Q36642170 | A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer |
| Q77128596 | A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD) |
| Q33746097 | A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer |
| Q43750753 | A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas. |
| Q45153919 | Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion |
| Q43472622 | Advanced colorectal cancer: which regimes should we recommend? |
| Q78128657 | Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study |
| Q35108451 | Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion |
| Q34427755 | Disease management considerations: disease management considerations |
| Q73356010 | Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients |
| Q33706220 | Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art. |
| Q50240420 | Effects of oxaliplatin-based chemotherapy on liver function--an analysis of impact and functional recovery using the LiMAx test |
| Q74028608 | Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen |
| Q47618482 | Gastrointestinal Tract Cancer Liaison Office: an attempt to organise clinical research in Europe |
| Q91871618 | Glucose Metabolites Exert Opposing Roles in Tumor Chemoresistance |
| Q73685102 | Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion |
| Q28379450 | High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy |
| Q43885255 | Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid |
| Q74456781 | In vitro concentration response studies and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols |
| Q39608101 | Influence of environment and healthcare structures on the survival of patients with colorectal cancer: a French population-based study |
| Q92839397 | Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data |
| Q34289631 | Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer |
| Q73597514 | Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand |
| Q42558059 | Neurotoxicity following weekly therapy with folinic acid and high-dose 5-fluorouracil 24-h infusion in patients with gastrointestinal malignancies |
| Q34572041 | New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer |
| Q44938504 | Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens |
| Q33998344 | Oxaliplatin clinical activity: a review |
| Q33499176 | Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer |
| Q43861062 | P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection |
| Q78250178 | Pharmacokinetic and pharmacodynamic comparison of two doses of calcium folinate combined with continuous fluorouracil infusion in patients with advanced colorectal cancer |
| Q43658197 | Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer |
| Q33361500 | Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. |
| Q36616449 | Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer |
| Q36621545 | Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil |
| Q72120609 | Prophylaxis of oral mucositis associated with chemoradiotherapy for oral carcinoma by Azelastine hydrochloride (Azelastine) with other antioxidants |
| Q33357849 | Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study |
| Q33341317 | Radioimmunotherapy of small-volume disease of metastatic colorectal cancer |
| Q73379732 | Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials |
| Q34754672 | Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. |
| Q43831198 | Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival |
| Q34070317 | Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer |
| Q40423849 | Role of leucovorin dosing and administration schedule |
| Q72534396 | SMS 201.995 (Sandostatin) enhances in-vitro effects of 5-fluorouracil in colorectal cancer |
| Q73355992 | Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers |
| Q33332077 | Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study |
| Q50941709 | Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo. |
| Q38441178 | Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up |
| Q34616010 | Treatment of liver metastases, an update on the possibilities and results |
| Q33360849 | Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract |
| Q40136672 | Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial |
| Q73869659 | [Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers. Groupe d'étude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD)] |
| Q71672064 | [What is the value of arterial chemotherapy in treatment of colorectal liver metastases] |
Search more.